The GLP-1 effect — why one drug is restructuring FMCG demand and making behavioral intelligence more urgent than ever
GLP-1 users are set to account for more than a third of US food and beverage sales by 2030. Households with at least one user are cutting grocery spend by 6 to 8% within months of adoption, with savory snacks down 10%. Kraft Heinz split the company. Nestlé launched its first major US food brand in three decades specifically for GLP-1 users. The demand shift is structural, accelerating, and geographically uneven — and standard campaign attribution models were not built to see it. Behavioral intelligence is.
GLP-1 users are set to account for more than a third of US food and beverage sales by 2030. Households with at least one user are cutting grocery spend by 6 to 8% within months of adoption, with savory snacks down 10%, desserts down substantially, alcohol down measurably. Kraft Heinz split the company. Nestlé launched its first major US food brand in three decades specifically for GLP-1 users. Nearly three dozen non-healthcare companies mentioned GLP-1 drugs on their earnings calls in early 2026, up from five two years prior. The demand shift is structural, accelerating, and geographically uneven — and standard campaign attribution models were not built to see it. Behavioral intelligence is.
Campaign attribution models report a single performance number against a consumer population that is splitting into structurally different behavioral segments. The split is geographically concentrated, demographically skewed, and invisible to any standard measurement infrastructure.
What is actually happening to FMCG demand
The GLP-1 story in food and beverage has been told primarily as a health and innovation story: drugs suppress appetite, consumers eat less, brands launch smaller portions and protein-enriched SKUs. That framing is accurate but incomplete. The more commercially consequential story is a measurement story — and it has received almost no attention.
Start with the scale of the behavioral shift. Circana's November 2025 research projects that households with GLP-1 users for weight loss will account for more than 35% of US food and beverage sales by 2030. The share of US adults taking GLP-1 medications more than doubled in less than two years, reaching 12.4% of the population by late 2025 according to Gallup, with a corresponding drop in the national obesity rate from 39.9% in 2022 to 37% in 2025.
Cornell University's research, published in the Journal of Marketing Research in January 2026, provides the most rigorous behavioral measurement to date. Using actual purchase records from approximately 150,000 US households matched against repeated surveys on GLP-1 use, the study found that households with at least one GLP-1 user cut grocery spend by approximately 6% within six months of adoption, with that figure rising to 8.2% among higher-income households who tended to be weight-loss rather than diabetes users. Spending on savory snacks fell by approximately 10%, with similar reductions in sweets, baked goods, and cookies.
PwC's analysis of Numerator data extends the picture further: GLP-1 users consume 40% fewer calories on average, with dessert consumption down 84%, alcohol down 33%, and fresh produce intake up over 70%. EY-Parthenon estimates that diet changes linked to GLP-1 use could mean up to $12 billion in lost snack sales over the next decade.
The industry response has been proportionally significant. Nestlé launched Vital Pursuit in 2024 — its first major US food brand in nearly three decades — specifically designed for GLP-1 users: portion-controlled frozen bowls, cauliflower crust pizzas, and sandwich melts aligned to the appetite profiles of users eating 700 fewer calories daily. Conagra added "GLP-1 friendly" labels to 26 Healthy Choice frozen meals. In the UK, within a single month in early 2026, Morrisons, Asda, Co-op, Iceland, M&S, and Ocado all launched dedicated GLP-1-compatible ready meal ranges. Kraft Heinz executed a full company split in September 2025, separating its faster-growing sauces and spreads from struggling processed food brands. Nearly three dozen non-healthcare companies mentioned GLP-1 drugs on their earnings calls in early 2026, up from five just two years prior.
PepsiCo, Mondelēz, Hershey, Danone, and General Mills have all described GLP-1 adaptation as a strategic priority. The GLP-1 effect is now a board-level conversation at most major FMCG companies. It has not yet become a measurement-level conversation — and that gap is where the most commercially consequential blindspot sits.
The measurement problem nobody is talking about
The standard framing of GLP-1's challenge for FMCG brands is a product innovation problem: how do you reformulate, resize, and reposition your portfolio to serve consumers whose appetites and dietary preferences have fundamentally changed? This is a real and urgent problem, and the industry is visibly working on it.
The measurement problem is different, less visible, and in some ways more urgent for brand marketing teams.
GLP-1 adoption is not uniformly distributed across the consumer population. It is concentrated along income, age, and geography lines in ways that have direct consequences for campaign measurement.
Weight-loss GLP-1 users skew younger and wealthier, according to the Cornell research. Higher-income households show adoption rates and grocery spend reductions significantly above average. Geographically, adoption is concentrated in urban centers with higher average incomes and greater healthcare access — which is also where many premium FMCG brands have their strongest distribution and highest per-unit revenue.
This geographic and demographic concentration creates a specific measurement problem: the consumer population that a brand's campaign reaches in a given market is now a mixture of GLP-1 users with structurally different behavioral economics and non-users whose purchase patterns are essentially unchanged. Standard campaign attribution models treat this as a single population. They report a blended ROAS or conversion metric that averages across both segments. The average obscures the divergence.
Consider what this means in practice. A brand running a national campaign for a snack product sees its TikTok attribution reporting an engagement rate similar to prior quarters. Its retail media buy reports a stable sponsored product ROAS. Its brand tracking shows steady awareness levels. None of these signals reveals that in the three zip codes where GLP-1 adoption among its target demographic has risen fastest, sell-through has declined by 8 to 12% — because the consumers who converted on that campaign were disproportionately in markets where GLP-1 adoption is low, while the high-adoption markets are generating campaign impressions that no longer convert to purchase at historical rates.
The attribution model is reporting a number. The number is accurate for the population that purchased. It is silent on the structural change in the population that used to purchase.
Why sell-through data reads the GLP-1 signal when attribution cannot
The reason GLP-1's behavioral impact is invisible to standard campaign attribution is structural, not technical. Attribution models measure what happened in the chain from ad exposure to digital conversion. GLP-1 changes the conversion probability of a segment of the exposed audience — but that change shows up in the population that does not convert, not in the population that does. Attribution models only see conversions. The changed behavior of non-converters is invisible to them by design.
Sell-through data at regional and SKU level reads a different signal. It does not measure who converted on an ad. It measures what actually moved off shelves, in which markets, for which products, over which time periods — relative to the baseline demand that preceded the current period.
When GLP-1 adoption rises in a geographic market, that market's sell-through for impulse-purchase, calorie-dense, and ultra-processed SKUs begins to diverge from historical trend lines. The divergence is not caused by campaign underperformance. It is caused by a structural change in the behavioral economics of a consumer segment within that market. A measurement system that connects sell-through data to the geographic footprint of campaign exposure — and that applies causal inference methods to separate campaign effect from baseline drift — can see this divergence.
More specifically, it can answer the question that the attribution model cannot: in this market, is sell-through underperforming because the campaign is not working, or because the audience for this product category is structurally contracting due to GLP-1 adoption? The distinction is commercially critical. A brand that cannot make it will cut campaign investment in high-adoption markets because the attribution numbers look poor — removing the one marketing lever that might still influence the remaining non-user segment in those markets. A brand that can make it will understand that the campaign is performing normally for the addressable audience, and that the addressable audience in that market is shrinking — requiring a portfolio response, not a campaign optimization.
The geographic skew and what it means for the German and European market
The European GLP-1 trajectory is materially different from the US pattern — but not in a direction that allows European FMCG brands to ignore the measurement problem.
In the US, GLP-1 adoption has been primarily demand-driven: consumer interest, employer insurance coverage, and relatively accessible private healthcare have pushed adoption to 12.4% of adults. In Europe, adoption is being governed by public health systems, prescribing pathway constraints, and national insurance decisions about which indications qualify for coverage. As of early 2026, European adoption sits at approximately 2% of adults — dramatically lower than the US, but growing and geographically concentrating in ways that matter for brand planning.
The countries with the strongest near-term potential for GLP-1 growth in Europe are the Nordic markets, where digital health infrastructure and early adoption of health innovation are advanced, France, where prescriber familiarity is growing, and Germany — though German statutory insurance rules limit coverage primarily to clear metabolic medical indications rather than weight loss, meaning German adoption will be narrower and more clinically concentrated in the near term.
The measurement implication for European brands is important precisely because the adoption pattern is narrower and more geographically specific than in the US. A 2% European average masks meaningful local concentrations in specific urban demographics that are early adopters of GLP-1 medications. For brands with strong distribution in urban German, Nordic, or French markets among higher-income younger consumer segments, the GLP-1 behavioral signal is already present in sell-through data even if it is not yet visible at the national measurement level.
ING's economists estimate that GLP-1 use could reduce European calorie intake by 2.5 to 3.5% by 2030. A 2 to 4% penetration in key adult demographics in high-adoption European markets would be sufficient to drive observable category-level demand change in impulse, indulgent, and ultra-processed segments. That is already within measurement range — if the measurement infrastructure is designed to see it.
What Lindt understood that most measurement systems cannot tell you
The most commercially instructive GLP-1 finding of 2025 comes from Lindt. The company published an internal analysis in March 2026 based on Circana data showing that GLP-1 households in the US represent 15% of all households but account for 17.5% of chocolate sales. Premium chocolate grew nearly 17% among GLP-1 users in 2025, compared to 6.5% among non-users.
The insight Lindt identified — that consumers reducing overall calorie intake are not eliminating indulgence but rather concentrating it in premium, high-quality occasions — is a finding that reframes the GLP-1 threat entirely for brands that can read the demand signal at this resolution. GLP-1 users consuming fewer calories are spending more per calorie on the occasions where they do indulge. Less volume, higher value. For premium positioned FMCG brands in confectionery, beverages, and personal care, this is not a threat. It is a repositioning opportunity — if the brand can see the geographic and demographic pattern in sell-through data rather than watching only the aggregate category volume decline.
This is precisely the kind of commercial intelligence that behavioral intelligence frameworks are designed to surface: not the aggregate national trend, but the geographic variation in how a demand shift plays out across different consumer segments, retail environments, and SKU profiles. A brand that can connect its campaign exposure patterns to regional sell-through outcomes — disaggregated by product tier and retailer type — can identify the Lindt pattern in its own category without waiting two years for aggregate market research to confirm it.
The brands that will navigate the GLP-1 transition most effectively are not the ones that respond fastest to the aggregate category trend. They are the ones that can read the geographic variation in how GLP-1 adoption is reshaping demand in specific markets, and direct both product portfolio and campaign investment accordingly.
That requires a measurement system that sits above the digital attribution layer and connects campaign signals to commercial outcomes at the resolution where the GLP-1 behavioral signal is actually readable.
The diagnostic question the GLP-1 era forces
The GLP-1 effect has introduced a new variable into the relationship between campaign investment and commercial outcome — one that was not present in any prior brand planning model. The variable is a segment of the consumer population with structurally different appetite economics, concentrated in specific geographies and demographics, growing steadily and unevenly, and completely invisible to standard attribution models.
For FMCG brands running national campaigns against a consumer population that is silently splitting into two behavioral segments, the question that standard measurement infrastructure cannot answer is the most commercially urgent one: is my campaign underperforming, or is the audience for my product in this market structurally contracting?
Attribution cannot answer it. Clean rooms cannot answer it. Platform ROAS cannot answer it. Brand tracking surveys cannot answer it with the speed and granularity required for campaign optimization decisions.
Sell-through data at market and SKU level, connected to campaign exposure patterns through causal inference methods, can answer it — because it measures the outcome rather than the input, at the resolution where the GLP-1 signal is actually present.
The GLP-1 era makes behavioral intelligence more urgent, not less. Because the demand variable that most complicates the relationship between campaign and commercial outcome is a behavioral one — physiologically embedded, geographically distributed, and invisible to every measurement system that was designed for a consumer population without it.
Sources and references
- Circana. GLP-1 weight loss drug households projected to account for more than 35% of US food and beverage sales by 2030. Via Food Dive, November 2025.
- Cornell University / Hristakeva et al. The No-Hunger Games: How GLP-1 Medication Adoption is Changing Consumer Food Demand. Journal of Marketing Research, January 2026. Grocery spend cut 5.3-6% within six months; 8.2% for higher-income households; savory snacks -10%; share of US households with at least one GLP-1 user rose from 11% in late 2023 to 16%+ by mid-2024.
- Gallup. National Health and Well-Being Index. 12.4% of US adults taking GLP-1 medications by late 2025; obesity rate fell from 39.9% in 2022 to 37% in 2025.
- PwC / Numerator. GLP-1 users consume 40% fewer calories on average; dessert consumption down 84%; alcohol down 33%; fresh produce up 70%+. Via Washington Post, December 2025.
- EY-Parthenon. GLP-1 diet changes could mean up to $12 billion in lost snack sales over the next decade.
- Vesper. Lindt analysis (Circana data, March 2026): GLP-1 households represent 15% of US households but 17.5% of chocolate sales; premium chocolate grew 17% among GLP-1 users vs 6.5% among non-users in 2025. Nearly three dozen non-healthcare companies mentioned GLP-1 on earnings calls early 2026, up from five two years prior.
- Big Chalk Analytics. Fall 2025 Industry Update. GLP-1 household penetration reached 12% in November 2025; projected 1.3-3.1% grocery food volume loss in 2026. Users eating less broadly rather than selectively cutting specific categories. December 2025.
- ING Economists. GLP-1 Drugs and European Food Demand. European adoption approximately 2% of adults vs 12% in US; GLP-1 use could reduce European calorie intake 2.5-3.5% by 2030; total near-term food demand impact approximately 0.25%. April 2026.
- FoodNavigator. Will GLP-1s Go Big in Europe in 2026? Nordic countries and France identified as highest European adoption potential; Germany limited by statutory insurance coverage rules. January 2026.
- Grocery Dive / Cornell University. Consumers on GLP-1s eat 700 fewer calories per day; spending on savory snacks and sugary beverages fell most; only fruit, leafy greens, and water saw overall increase. July 2025.
- Vesper / Grocery Dive. Nestlé Vital Pursuit launched 2024 — first major US Nestlé food brand in three decades. Conagra: first company to add "GLP-1 friendly" on-pack labeling (26 Healthy Choice meals). Kraft Heinz company split September 2025. UK: Morrisons, Asda, Co-op, Iceland, M&S, Ocado all launched GLP-1 ready meal ranges within a single month, early 2026.
Veinera connects campaign signals to sell-through outcomes at market and SKU level — providing the measurement infrastructure that reads GLP-1's uneven demand shift across your geographic footprint and separates campaign effect from structural audience contraction. Book a 30-minute walkthrough, no commitment.
Related reading
- The offline data desert — why the most valuable behavioral signal is the hardest to reach · Apr 19, 2026
- The private label squeeze — why behavioral intelligence is the most important defense FMCG brands have right now · Jun 14, 2026
- From share of voice to share of shelf — why behavioral intelligence resolves the brand-versus-performance debate · Jul 5, 2026
